DOI: https://doi.org/10.22141/2308-2097.53.1.2019.163457

Functional constipation at a young age. Place of macrogol 4000 (Forlax) in the treatment

A.E. Dorofeiev, M.M. Rudenko, Yu.V. Zhyhal

Abstract


Background. Considering the wide prevalence of functional constipation (FC) at a young age, we set ourselves the task of comparing the effectiveness of osmotic laxative macrogol 4000 (Forlax) in the treatment of FC in adolescents and young adults in the Ukrainian population. Materials and methods. We have examined 35 young adults aged 19 to 25 years (average age 24.10 ± 0.33 years) and 28 children in late adolescence aged 15 to 19 years (average age 15.90 ± 0.21 years). In the group of young adults, female patients slightly dominated (20/15), and among adolescents, both sexes were equally represented (14/14). It was an open-label, multi-center study. Patients with FC were monitored at the Kyiv gastrocenter and Kramatorsk Children’s Territorial Medical Association. The diagnosis of FC in the adult and adolescent groups was made based on the well-known Rome IV criteria. The frequency of bowel movements during the week was evaluated, as well as the shape of the stool according to the Bristol stool scale. The general state of health and severity of abdominal distention were evaluated on a 10-centimeter Visual analogue scale. Macrogol Forlax was administered as 10 g of powder dissolved in a glass of water once a day in the morning. With insufficient effect after 7 days of treatment, the dose was doubled. The duration of the drug use was 14 days. Results. After two weeks of treatment, the following results were obtained. The frequency of bowel movements was 4.36 ± 0.21 (p < 0.001) once a week, the shape of the stool according to the Bristol stool scale was 3.48 ± 0.22 (p < 0.001), the need for excessive straining was observed in 6 (17.1 %) patients, a feeling of incomplete defecation persisted in 4 (11.4 %) persons. The general state of health according the Visual analogue scale was 5.41 ± 0.30 cm (p = 0.008), the feeling of bloating — 2.07 ± 0.22 cm (p = 0.08). Conclusions. In the Ukrainian population, macrogol (Forlax) has a significant laxative effect in both young adults and adolescents suffering from functional constipation. According to our data, the efficiency reached 85.7 % in adults, and 89.3 % in adolescents.


Keywords


constipation; functional constipation; laxatives; macrogol

References


ECCO guidelines for ulcerative colitis. 2016. Available from: http://www.e-guide.ecco-ibd.eu. Accessed: February 2017.

Nahurna YaV. Screening for Bowel Disease in the Population of the Western Region of Ukraine. Gastroenterologia. 2015;(55):46-49. (in Ukrainian).

Moum B, Hovde Ø, Høivik ML. What have we learnt about the role of the environment and natural course of IBD in the new Millenium? 20-year follow-up of the IBSEN cohort. Dig Dis. 2014;32 Suppl 1:2-9. doi: 10.1159/000367818.

Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: result from Norwegian population-based cohort. Gastroenterology. 2007 Aug;133(2):412-22.

Nahurna YaV. Factory risiku chronichnih zahvoruvan kishechniku sered naselennya zahidnogo region Ukraini [Risk factors of chronic bowel diseases in patients of Westen Ukraine]. Diss PhD med sci. 2017. 17 p.

StepanovYuM, Skyrda ІYu, Petishko ОP. Chronic inflammatory bowel diseases: epidemiological features in Ukraine. Gastroentrologia. 2017;51(2):97-105. doi: 10.22141/2308-2097.51.2.2017.101703.

Dorofeyev АE, Kharchenko NV, Rudenko NN, et al. The peculiarities of genetic profile in patients with inflammatory bowel disease in Ukraine and strategy for their management. Modern Gastroenterology. 2017;(93):22-29.

Marrakchi R, Moussa A, Ouerhani S, et al. Interleukin 10 promoter region polymorphisms in inflammatory bowel disease in Tunisian population. Inflamm Res. 2009 Mar;58(3):155-60. doi: 10.1007/s00011-008-8265-5.

Legaki Е, Gazouli М. Influence of environmental factors in the development of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):112-25. doi: 10.4292/wjgpt.v7.i1.112.

Harbord M, Eliakim R, Bettenworth D, et al., Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017 Jul 1;11(7):769-784. doi: 10.1093/ecco-jcc/jjx009.

D’Haens G, van Bodegraven AA. Mesalazine is safe for the treatment of IBD. Gut. 2004;53(1):154-158.

Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001 Aug;7(3):237-42.

De Vos M. Clinical pharmacokinetics of slow release mesalazine. Clin Pharmacokinet. 2000 Aug;39(2):85-97. doi: 10.2165/00003088-200039020-00001.




Copyright (c) 2019 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2020

 

   Seo анализ сайта